Tag Archive > Sny

Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation

Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Sanofi-aventis startet neues großes Register mit über 10.000 Vorhofflimmer-Patienten weltweit

Paris, Frankreich – 16. November 2009 – (ots) – Das RealiseAF-Register wird dazu beitragen, das kardiovaskuläre Risikoprofil von Vorhofflimmerpatienten besser zu definieren und zu verstehen sowie kardiovaskuläre Folgen besser zu charakterisieren
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) gab heute den Start des RealiseAF-Registers bekannt (Real life global Survey Evaluating patients with Atrial Fibrillation), einem internationalen [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation

Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Superior Efficacy-dose Ratio for Lantus(R) Over detemir

Paris (ots/PRNewswire) – – 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R)
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union

Paris (ots/PRNewswire) – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone – 400mg Tablets).
The CHMP has recommended the approval of [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter
- U.S Commercial Launch Planned for the Summer of 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

Paris and Brisbane, California (ots/PRNewswire) – – Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq(R) (dronedarone) in Atrial Fibrillation

Paris (ots/PRNewswire) – – Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation
Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

New England Journal of Medicine veröffentlicht Ergebnisse der Meilensteinstudie ATHENA mit Dronedaron bei Vorhofflimmern

Paris, Frankreich (ots) -
– Dronedaron reduziert das Risiko für kardiovaskulär bedingte
Krankenhausaufenthalte oder Tod bei Patienten mit Vorhofflimmern
signifikant um 24 Prozent –
Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) gab heute bekannt, dass die ATHENA Studie im New England Journal of [...]

Continue reading

, , , , , , , , , , , , , , , , , ,